◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Alivus Life Sciences Limited (ALIVUS) Financial History

Name: Alivus Life Sciences Limited (ALIVUS) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Alivus Life Sciences Limited (ALIVUS) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 2,272 employees. Its market capitalization is roughly ₹176 billion. In the fiscal year ended 2026-03-31, ALIVUS reported ₹25.0B in revenue and ₹5.6B in net income.

Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia.

Interactive charts & full statements →

ALIVUS Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹25.0B	₹23.4B	₹21.8B	₹20.5B	—
Gross Profit	₹13.9B	₹12.2B	₹11.6B	₹10.2B	—
Operating Income (EBIT)	₹7.2B	₹6.2B	₹6.2B	₹6.0B	—
Net Income	₹5.6B	₹4.9B	₹4.7B	₹4.7B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALIVUS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Total Revenue	₹6.4B	₹6.9B	₹6.7B	₹6.0B	₹6.5B
Gross Profit	₹3.9B	₹4.2B	₹4.0B	₹3.3B	₹3.7B
Operating Income (EBIT)	₹1.9B	₹1.9B	₹2.1B	₹1.6B	₹1.8B
Net Income	₹1.6B	₹1.6B	₹1.5B	₹1.2B	₹1.4B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALIVUS Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹613M)	—	(₹2.8B)	(₹3.9B)	(₹1.3B)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALIVUS Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹39.8B	₹34.1B	₹28.5B	₹27.0B	—
Total Liabilities	₹6.5B	₹5.9B	₹5.2B	₹5.6B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALIVUS viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

SHILPAMED · Shilpa Medicare Limited — ₹200 billion
4887 · Sawai Group Holdings Co., Ltd. — JPY 189 billion
ERIS · Eris Lifesciences Limited — ₹183 billion
4553 · Towa Pharmaceutical Co., Ltd. — JPY 183 billion
ASTRAZEN · AstraZeneca Pharma India Limited — ₹169 billion
JUBLPHARMA · Jubilant Pharmova Limited — ₹169 billion
4547 · Kissei Pharmaceutical Co., Ltd. — JPY 168 billion
COHANCE · Cohance Lifesciences Limited — ₹168 billion

← ALIT All “A” companies ALK →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.